Immunotherapy for stage 4 prostate cancer is revolutionizing the way advanced disease is being treated, offering hope for patients worldwide. Unlike conventional treatment methods such as surgery and ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses. That connection is ...

Delivery of a new nanoparticle-based immunotherapy to perivascular tumour-associated macrophages (TAMs) in androgen deprivation therapy (ADT)-treated prostate tumours may increase antitumour immunity ...

New research has shown that immunotherapy can be effective in treating prostate cancer in men who are selected based on the genetic characteristics of their tumors. In a recent study, it was found ...

Add Yahoo as a preferred source to see more of our stories on Google. Researchers at the University of Arizona Health Sciences have uncovered a promising new approach for treating prostate cancer ...

A new form of immunotherapy using innovative nanoparticles can delay resistance to hormone therapy and help men with prostate cancer live longer. Researchers from the University of Sheffield have ...

In this exclusive MedPage Today video, Tanya Dorff, MD, of City of Hope in Duarte, California, discusses two prostate cancer immunotherapy studies presented at the recent American Society of Clinical ...

Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses. Black men with ...

Syncromune is advancing SYNC-T Therapy SV-102 in the ongoing Phase 2 LEGION-100 study (NCT06533644), which is actively enrolling across multiple sites in the U.S. Please visit www.legion100trial.com ...

CHICAGO -- An investigational viral immunotherapy (CAN-2409; aglatimagene besadenovec) combined with a prodrug improved disease-free survival (DFS) when added to standard curative-intent radiotherapy ...

(From left) A research team led by Noel Warfel, PhD, and including doctoral candidate Caitlyn Flores published a paper in Cancer Immunology Research detailing a potential new therapy for prostate ...